Antibodies for bioanalysis and drug monitoring of sarilumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug sarilumab (Kevzara) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to sarilumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Sarilumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Sarilumab Inhibitory

Type 1

HCA410

AbD49514ia

hIgG1

<0.1

ADA assay

Order HCA410

HCA411

AbD49516ia

hIgG1

0.9

ADA assay

Order HCA411

HCA412

AbD49520ia

hIgG1

2

ADA assay

Order HCA412

TZA046

AbD5019ad

Fab-F-Spy2-H

0.02

PK bridging ELISA (capture)

Order TZA046

TZA047

AbD51309ad

Fab-F-Spy2-H

0.3

PK bridging ELISA (detection)

Order TZA047

TZA047P

AbD51309pap

Fab2-FH-X22-HRP

0.3

PK bridging ELISA (detection)

Order TZA047P

* Affinity measured in the monovalent Fab format
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher


Anti-Sarilumab Inhibitory Antibodies (Type 1)

Type 1 anti-sarilumab antibodies inhibit the binding of the drug sarilumab to its target, the human interleukin-6 receptor (IL-6R). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


TrailBlazer Antibodies

TrailBlazer™ Antibodies, clones TZA046 (AbD5019ad) and TZA047 (AbD51309ad) have a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Sarilumab PK bridging ELISA using antibodies TZA046 and TZA047P.

Fig. 1. Sarilumab PK bridging ELISA using antibodies TZA046 and TZA047P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.


ADA Bridging ELISA


Fig. 2. Sarilumab ADA bridging ELISA using antibody HCA410, HCA411 and HCA412.

Fig. 2. Sarilumab ADA bridging ELISA using antibody HCA410, HCA411 and HCA412.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).



Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.